轉(zhuǎn)自國資委:
China National Pharmaceutical Group Co., Ltd. (Sinopharm) has used its technology and capacity advantages to develop and produce nucleic acid diagnostic reagents soon after the outbreak of novel coronavirus.
Distribution of its detection kit throughout the country is now beginning.
Meanwhile, Sinopharm is actively stockpiling virus treatment products and conducting further research and development of the antiserum. It has quickly organized workers and material resources to prepare for development of a vaccine.
China National Pharmaceutical Group Co., Ltd. researches virus nucleic acid diagnostic reagents. [Photo/sasac.gov.cn]
As a leading pharmaceutical company in Wuhan, where the outbreak of the novel coronavirus occurred, Sinopharm's Hubei branch has provided 40,460 sets of protective clothing and 111,360 surgical gowns, 360,000 N95 masks, 24,900 surgical masks, and 196,000 shoe covers.
It has also supplied 2.92 million boxes of medicine for the clinical application of anti-influenza virus symptom treatment.
Sinopharm Group Zhonglian Pharmaceutical Co., Ltd has organized inventory build-up, production scheduling and logistics of three traditional Chinese medicine products that help treat the symptoms caused by pneumonia to ensure their timely supply.
Sinopharm Group Zhonglian Pharmaceutical Co., Ltd makes efforts to guarantee the timely supply of three traditional Chinese medicine products that help treat the symptoms caused by pneumonia. [Photo/sasac.gov.cn]
China Resources Pharmaceutical Group Limited, a subsidiary of China Resources (Holdings) Group Co., Ltd (CR), has made every effort to ensure the supply and stable price of drugs, medical apparatus and instruments related to the outbreak of novel coronavirus-caused pneumonia, and established dynamic monitoring, analysis and reporting mechanisms for supply, storage and distribution.
CR's other two subsidiaries, China Resources Healthcare Group Limited and China Resources Medical Holdings Company Limited, strengthened the screening of patients with fever, quickly isolated suspected patients and paid close attention to and implemented the deployment plans of the local health commission.
Meanwhile, they purchased necessary protective equipment and conducted standard protection to prevent and control infection in the hospital.
China Resources Pharmaceutical Group Limited, a subsidiary of China Resources Group, makes every effort to ensure the supply and stable prices of drugs, medical apparatus and instruments. [Photo/sasac.gov.cn]
China General Technology Group took immediate multiple measures simultaneously in medical treatment, material supplies and security.
Hubei General Technology (Wuhan) and its subsidiaries in Shiyan, Xiangyang, Yichang, Huangshi and Xiaogan have stayed in line with the local governments' work for epidemic prevention to ensure they could meet the people's needs for epidemic prevention drugs during the Spring Festival holiday and for distribution of safe high quality drugs.
China General Technology Group Yichang General Medicine Corporation has collected 300,000 surgical protective masks throughout the country, and worked overtime to distribute them to pharmacies and clinics in Yichang.
Hospitals affiliated to Genertec Universal Medical Group Co., Ltd have been mobilized in an emergency response to the outbreak.
Medical workers voluntarily gave up their holidays and fought on the front lines. Seven of the hospitals were designated for novel coronavirus-caused pneumonia treatment and isolation.
In accordance with arrangements made by relevant government departments, Jiuzhiyang Infrared System Co., Ltd of China State Shipbuilding Corporation Limited put its production layout on an emergency basis and expanded output of infrared temperature measuring products.
Jiuzhiyang Infrared is at full production and working overtime with the government to fight the novel coronavirus.
Jiuzhiyang Infrared System Co., Ltd of China State Shipbuilding Corporation Limitd urgently adjusted its production capacity layout and expanded output of infrared temperature measuring products. [Photo/sasac.gov.cn]
轉(zhuǎn)自國資委:
China National Pharmaceutical Group Co., Ltd. (Sinopharm) has used its technology and capacity advantages to develop and produce nucleic acid diagnostic reagents soon after the outbreak of novel coronavirus.
Distribution of its detection kit throughout the country is now beginning.
Meanwhile, Sinopharm is actively stockpiling virus treatment products and conducting further research and development of the antiserum. It has quickly organized workers and material resources to prepare for development of a vaccine.
China National Pharmaceutical Group Co., Ltd. researches virus nucleic acid diagnostic reagents. [Photo/sasac.gov.cn]
As a leading pharmaceutical company in Wuhan, where the outbreak of the novel coronavirus occurred, Sinopharm's Hubei branch has provided 40,460 sets of protective clothing and 111,360 surgical gowns, 360,000 N95 masks, 24,900 surgical masks, and 196,000 shoe covers.
It has also supplied 2.92 million boxes of medicine for the clinical application of anti-influenza virus symptom treatment.
Sinopharm Group Zhonglian Pharmaceutical Co., Ltd has organized inventory build-up, production scheduling and logistics of three traditional Chinese medicine products that help treat the symptoms caused by pneumonia to ensure their timely supply.
Sinopharm Group Zhonglian Pharmaceutical Co., Ltd makes efforts to guarantee the timely supply of three traditional Chinese medicine products that help treat the symptoms caused by pneumonia. [Photo/sasac.gov.cn]
China Resources Pharmaceutical Group Limited, a subsidiary of China Resources (Holdings) Group Co., Ltd (CR), has made every effort to ensure the supply and stable price of drugs, medical apparatus and instruments related to the outbreak of novel coronavirus-caused pneumonia, and established dynamic monitoring, analysis and reporting mechanisms for supply, storage and distribution.
CR's other two subsidiaries, China Resources Healthcare Group Limited and China Resources Medical Holdings Company Limited, strengthened the screening of patients with fever, quickly isolated suspected patients and paid close attention to and implemented the deployment plans of the local health commission.
Meanwhile, they purchased necessary protective equipment and conducted standard protection to prevent and control infection in the hospital.
China Resources Pharmaceutical Group Limited, a subsidiary of China Resources Group, makes every effort to ensure the supply and stable prices of drugs, medical apparatus and instruments. [Photo/sasac.gov.cn]
China General Technology Group took immediate multiple measures simultaneously in medical treatment, material supplies and security.
Hubei General Technology (Wuhan) and its subsidiaries in Shiyan, Xiangyang, Yichang, Huangshi and Xiaogan have stayed in line with the local governments' work for epidemic prevention to ensure they could meet the people's needs for epidemic prevention drugs during the Spring Festival holiday and for distribution of safe high quality drugs.
China General Technology Group Yichang General Medicine Corporation has collected 300,000 surgical protective masks throughout the country, and worked overtime to distribute them to pharmacies and clinics in Yichang.
Hospitals affiliated to Genertec Universal Medical Group Co., Ltd have been mobilized in an emergency response to the outbreak.
Medical workers voluntarily gave up their holidays and fought on the front lines. Seven of the hospitals were designated for novel coronavirus-caused pneumonia treatment and isolation.
In accordance with arrangements made by relevant government departments, Jiuzhiyang Infrared System Co., Ltd of China State Shipbuilding Corporation Limited put its production layout on an emergency basis and expanded output of infrared temperature measuring products.
Jiuzhiyang Infrared is at full production and working overtime with the government to fight the novel coronavirus.
Jiuzhiyang Infrared System Co., Ltd of China State Shipbuilding Corporation Limitd urgently adjusted its production capacity layout and expanded output of infrared temperature measuring products. [Photo/sasac.gov.cn]